Company Overview
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. It offers CARDAMYST (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. The company is also developing etripamil for the indication of atrial fibrillation with rapid ventricular rate (AFib-RVR). It has a license and collaboration agreement with Corxel Pharmaceuticals to develop and commercialize etripamil. Milestone Pharmaceuticals Inc.was incorporated in 2003 and is headquartered in Montreal, Canada.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -35.34% |
| 6 Months: | -32.63% |
| 3 Months: | -8.54% |
| 1 Month: | -7.79% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)46.48 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 61.9% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | MIST Milestone Pharmaceuticals Inc. PHARMA | 1.12 | -1.72 | $139.44M | 0.00% | -62.40% | - | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | - | - | 238.00K |
| Operating Income | -4.25M | -3.68M | -5.79M | -10.93M | -14.33M | -13.72M | -16.76M | -13.11M | -12.09M | -12.59M | 712.00K | -14.27M | -14.05M | -16.81M | -15.03M | -15.50M | -16.44M | -15.36M | -10.48M | -9.66M | -9.62M | -20.52M | -12.53M | -11.83M | -23.66M |
| Net Income | -4.18M | -3.59M | -5.70M | -10.45M | -13.66M | -12.83M | -16.34M | -12.98M | -11.98M | -12.51M | 770.00K | -14.22M | -14.01M | -16.65M | -14.56M | -14.95M | -16.04M | -15.08M | -10.35M | -9.36M | -9.44M | -20.76M | -12.97M | -11.92M | -26.07M |
| Diluted EPS | - | - | - | - | - | - | - | -0.53 | - | -0.30 | 0.02 | -0.34 | -0.33 | -0.39 | -0.34 | -0.35 | -0.37 | -0.35 | -0.21 | -0.14 | -0.14 | -0.31 | -0.20 | -0.12 | -0.20 |
| R&D Expense | 3.09M | 2.55M | 3.91M | 7.76M | 10.53M | 9.54M | 11.87M | 8.62M | 8.23M | 8.60M | 9.43M | 9.73M | 8.77M | 10.66M | 9.83M | 10.26M | 8.62M | 6.72M | 3.64M | 2.81M | 3.96M | 4.98M | 3.67M | 3.94M | 3.25M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating Income | -23.82M | -57.88M | -50.71M | -43.07M | -59.64M | -61.10M | -42.10M | -62.14M |
| Net Income | -23.18M | -55.23M | -49.97M | -42.85M | -58.39M | -59.69M | -41.52M | -63.06M |
| Diluted EPS | - | - | -1.70 | -1.02 | -1.38 | -1.39 | -0.67 | -0.75 |
| R&D Expense | 16.85M | 41.98M | 34.49M | 38.67M | 39.83M | 31.05M | 14.36M | 18.11M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 88.08M | 123.43M | 149.97M | 119.85M | 74.48M | 75.23M | 75.50M | 113.56M |
| Total Equity | 25.98M | 83.55M | 114.92M | 143.12M | 112.60M | 66.35M | 16.77M | 13.15M | 41.77M |
| Cash & Equivalents | - | 85.95M | 119.82M | 72.31M | 114.14M | 7.64M | 13.76M | 25.31M | 73.05M |
| Long Term Debt | - | - | 0 | - | - | - | 49.77M | 53.35M | 57.19M |
| Total Liabilities | - | 4.53M | 8.51M | 6.86M | 7.25M | 8.13M | 58.45M | 62.35M | 71.79M |
| Current Liabilities | - | 4.53M | 8.33M | 6.16M | 6.78M | 6.14M | 7.23M | 8.13M | 13.98M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -21.05M | -51.15M | -50.73M | -33.22M | -52.47M | -46.42M | -28.85M | -49.04M |
| Investing Cash Flow | 16.00M | -384.00K | -70.00M | 70.00M | -57.12M | 4.76M | 8.28M | 11.25M |
| Financing Cash Flow | 80.11M | 85.41M | 73.22M | 5.05M | 3.09M | 47.79M | 32.12M | 85.53M |
| Capital Expenditure | -5.00K | -413.00K | - | - | -272.00K | -112.00K | -33.00K | -302.00K |
| Free Cash Flow | -21.05M | -51.56M | - | - | -52.74M | -46.54M | -28.88M | -49.34M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - | - | - |
| ROE % | -27.8% | -48.1% | -34.9% | -38.1% | -88.0% | -355.9% | -315.8% | -151.0% |
| ROCE % | -28.5% | -50.3% | -35.3% | -38.1% | -87.3% | -89.8% | -62.5% | -62.4% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Pavaki Capital Management LLC | 7.28% | 9.07M | $8.30M |
| 2 | RTW Investments LP | 6.29% | 7.83M | $7.17M |
| 3 | Propel Bio Management, LLC | 5.97% | 7.43M | $6.80M |
| 4 | Point72 Asset Management, L.P. | 4.35% | 5.41M | $4.96M |
| 5 | Simplify Asset Management, Inc. | 2.69% | 3.35M | $3.07M |
| 6 | Millennium Management Llc | 2.52% | 3.14M | $2.88M |
| 7 | Two Sigma Investments, LP | 1.64% | 2.04M | $1.87M |
| 8 | Marshall Wace LLP | 1.44% | 1.80M | $1.65M |
| 9 | Kalehua Capital Management LLC | 1.02% | 1.27M | $1.16M |
| 10 | Lion Point Capital, LP | 0.66% | 820.00K | $750.96K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for MIST
Three investor events are set for Boston and New York, with Milestone joining - Stock Titan
<a href="https://news.google.com/rss/articles/CBMisgFBVV95cUxQOURaZEtqQkJkMmNidW9zcm9md2doMmI5MGFIMG00VlM3REY2bnRmc1lqemF2MmcwYjR3bTVEdnNRNDR4MHBDTDJKQUJGdWN0RTlHWEJnOTAycXRzRDV6OGMyZ1Zjb0ZnM3VGX1JZc09oc3dnckxlbzdUNkNhUXVNaHFQMnJyMFdwQ0dnQ2…
Milestone Pharmaceuticals shares rise as first patient enters Phase 3 AFib trial - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxPT1YyQTNod19fSnF4dGZxLV85UEJEeEV4UTR4ZHZUM0t1b2ZIYUNrMV80cV9DZUpLVEhPcW1qdVVzZVZPV0wtZ3I1YWJrYmI1dkUybzlsWmNiTjFXOVZfcmJ3blphd3dxVGNmY0U2ZmJXVGdiZzJLdk1ReDF5QUhqQmRJa1pNWU9DUTNhN3…
Milestone Pharmaceuticals: Reiterating Sell As The Losses Compound (NASDAQ:MIST) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMisgFBVV95cUxNSUczUDhCd2E3dDlIaWkwWkpqSHItQzJFNGl6UVRJalc2RlV6SDdFNXVVcG1mYmpaMW1KdmsxV0M2VElsLWJ5X3dLOTFCZ0Jyc0xSblcyN1VfRmNxcXdPRG1wZ3JXVUNvbVQ0blZPWWdHc2JpT0JvVXFQYWRvRldZd1AwM3lQaE40UjhRZ2…
Milestone Pharmaceuticals stock gains on Phase 3 AFib trial - Investing.com
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxQS21HZ0dUWXVQcDdta0RudEU1ZlcxVlgyNEdYLXc4S2FOMkRRMmh1U3BFazhMeEtYY3ZMeXJBSFZiejMxUU5yOXNvUGJfY1NMYnFXYVFhXy1hSFZBcVdaWmI1eU1lZ3FiTUJkUzJUekJZeW5lNWFPRHVWb2NvT2hDa004RzNidjNvRjcteF…
MILESTONE PHARMACEUTICLS ($MIST) Releases Q2 2026 Earnings - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxOcFZ4Zk10VHQ2WmQtMmRfOXRCUUtZdTdMSzVsQ3BSWFB1dlg0MGdqeFlYMVpKdEs4aWZRUzJGNXFJUjl4MlNOMloyUmpQQXN6NG5DNHltZy1DOGp4LTJNeTYyWl95LXp3TXNfQzcyRHo0Z2lJXy1uVkV4MXZGZE5WX2cxU3RtLTQ1SWJuek…
Milky Mist IPO Listing: Shares Debut at ₹165, Gain 18%; Stock Rises 29.64% From Issue Price - indiainfoline.com
<a href="https://news.google.com/rss/articles/CBMiygFBVV95cUxPY3FwaTM5bkhCT3QzcHJwY3QxUWZGM3BKOHUwNFhuU25rcUxfZlJJd3p6emE2b200VFJsUlp6bXpJaFhxTVd4MXJkRzVkX2VHNEdhbjRqRXF6ZE02aVRaNjdxaGt2bE4zSnM0cVF6Wk9ZT1NaY2VCUkc3Vk9YbGRPUEVYVUZVbWlmeTd2WU…
MIST — Frequently Asked Questions
What is the current share price of Milestone Pharmaceuticals Inc. (MIST)?
As of 2026-09-19 21:16 PDT, Milestone Pharmaceuticals Inc. (MIST) trades at $1.12 on NasdaqGS. Its 52-week range is $1.01 to $2.95.
What is the market capitalisation of MIST?
Milestone Pharmaceuticals Inc. (MIST) has a market capitalisation of $139.44M on NasdaqGS.
What is the P/E ratio of MIST?
MIST trades at a trailing price-to-earnings (P/E) ratio of -1.72. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 7.10.
Is MIST a good stock to buy?
This page provides a data-driven analysis of Milestone Pharmaceuticals Inc. (MIST), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.